UncategorizedFDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the Emergency Treatment of Known or Suspected Opioid Overdose Posted on July 7, 2026July 7, 2026 by dekidd314@gmail.com Continue reading →
UncategorizedPurdue Pharma Announces Landmark Agreement with Oklahoma to Advance the Treatment of Addiction Posted on July 7, 2026July 7, 2026 by dekidd314@gmail.com Continue reading →
UncategorizedEisai and Purdue Pharma Announce Buy Out of Purdue’s Rights in Worldwide Collaboration to Develop and Commercialize Lemborexant Posted on July 7, 2026July 7, 2026 by dekidd314@gmail.com Continue reading →
UncategorizedPurdue Pharma Announces First Participant Enrolled in Clinical Study Assessing Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose Posted on July 7, 2026July 7, 2026 by dekidd314@gmail.com Continue reading →
UncategorizedPurdue Pharma Presents Considerations in Opioid Comparator Selection at the College on Problems of Drug Dependence Annual Scientific Meeting Posted on July 7, 2026July 7, 2026 by dekidd314@gmail.com Continue reading →
UncategorizedJulie Ducharme, BPharm, MSc, PhD Named Vice President and Chief Scientific Officer of Purdue Pharma L.P. Posted on July 7, 2026July 7, 2026 by dekidd314@gmail.com Continue reading →
UncategorizedPurdue Pharma L.P. and the National Center for Wellness & Recovery at Oklahoma State University Announce Collaboration Around Research to Address the Opioid Addiction Crisis Posted on July 7, 2026July 7, 2026 by dekidd314@gmail.com Continue reading →
UncategorizedThe Prescription Drug Safety Network Significantly Expands Its Reach in Year 2 and Reports an Average 48% Knowledge Gain Nationwide Posted on July 7, 2026July 7, 2026 by dekidd314@gmail.com Continue reading →
UncategorizedHello world! Posted on July 6, 2026 by dekidd314@gmail.com Welcome to WordPress. This is your first post. Edit or delete it, then start writing! Continue reading →
